Zacks: Analysts Expect Orexigen Therapeutics, Inc. (OREX) to Announce -$2.13 Earnings Per Share
Brokerages expect Orexigen Therapeutics, Inc. (NASDAQ:OREX) to post earnings of ($2.13) per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Orexigen Therapeutics’ earnings. Orexigen Therapeutics reported earnings per share of ($1.01) in the same quarter last year, which indicates a negative year over year growth rate of 110.9%. The firm is scheduled to issue its next quarterly earnings results on Thursday, November 2nd.
On average, analysts expect that Orexigen Therapeutics will report full year earnings of ($10.77) per share for the current financial year. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow Orexigen Therapeutics.
Orexigen Therapeutics (NASDAQ:OREX) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.82) EPS for the quarter, beating the Zacks’ consensus estimate of ($2.40) by $0.58. Orexigen Therapeutics had a negative net margin of 120.77% and a negative return on equity of 824.15%. The firm had revenue of $23.36 million for the quarter, compared to analysts’ expectations of $20.00 million. During the same quarter in the previous year, the business posted ($1.73) EPS. The company’s quarterly revenue was up 199.9% on a year-over-year basis.
A number of equities analysts have recently issued reports on OREX shares. Zacks Investment Research raised Orexigen Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, July 11th. ValuEngine raised Orexigen Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Tuesday, July 11th.
Shares of Orexigen Therapeutics (OREX) opened at 1.9607 on Friday. The stock’s 50 day moving average is $2.20 and its 200-day moving average is $2.69. Orexigen Therapeutics has a one year low of $1.65 and a one year high of $5.70. The company’s market cap is $30.25 million.
Hedge funds have recently modified their holdings of the stock. Wells Fargo & Company MN boosted its position in Orexigen Therapeutics by 2.5% during the second quarter. Wells Fargo & Company MN now owns 45,638 shares of the biopharmaceutical company’s stock valued at $132,000 after purchasing an additional 1,100 shares in the last quarter. KCG Holdings Inc. boosted its position in Orexigen Therapeutics by 30.0% during the first quarter. KCG Holdings Inc. now owns 43,954 shares of the biopharmaceutical company’s stock valued at $151,000 after purchasing an additional 10,139 shares in the last quarter. Finally, EcoR1 Capital LLC bought a new stake in Orexigen Therapeutics during the first quarter valued at about $405,000. 39.66% of the stock is currently owned by institutional investors.
Orexigen Therapeutics Company Profile
Orexigen Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Orexigen Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orexigen Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.